BRCA1 and posterior cortical atrophy: In this work, we carry out CRISPR screens in four BRCA1/2-proficient PCa cell lines with the goal of expanding the use of PARPis beyond BRCA1/2 mutation carriers and finding undefined synthetically lethal interactions.